GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PTC Therapeutics Inc (NAS:PTCT) » Definitions » Price-to-Tangible-Book

PTCT (PTC Therapeutics) Price-to-Tangible-Book : (As of May. 08, 2025)


View and export this data going back to 2013. Start your Free Trial

What is PTC Therapeutics Price-to-Tangible-Book?

As of today (2025-05-08), PTC Therapeutics's share price is $40.76. PTC Therapeutics's Tangible Book per Share of Mar. 2025 for the quarter that ended in Mar. 2025 was $-4.88. Hence, PTC Therapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for PTC Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, PTC Therapeutics's highest Price to Tangible Book Ratio was 97.00. The lowest was 1.11. And the median was 4.86.

PTCT's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.57
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, PTC Therapeutics's share price is $40.76. PTC Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2025 was $-2.34. Hence, PTC Therapeutics's P/B Ratio of today is .


PTC Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for PTC Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Price-to-Tangible-Book Chart

PTC Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PTC Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PTC Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, PTC Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PTC Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Price-to-Tangible-Book falls into.


;
;

PTC Therapeutics Price-to-Tangible-Book Calculation

PTC Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2025 )
=40.76/-4.878
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


PTC Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


PTC Therapeutics Business Description

Traded in Other Exchanges
Address
500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Executives
Lee Scott Golden officer: Chief Medical Officer 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Eric Pauwels officer: Chief Business Officer 550 HILLS DRIVE, BEDMINSTER NJ 07921
Stephanie Okey director C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Mark Elliott Boulding officer: Exec. VP and CLO C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Allan Steven Jacobson director PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Neil Gregory Almstead officer: EVP Research Pharma Ops & Tech C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Pierre Gravier officer: CHIEF FINANCIAL OFFICER C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Matthew B. Klein officer: Chief Development Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Christine Marie Utter officer: Principal Financial Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Michael Schmertzler director 110 WASHINGTON STREET, SUITE 1300, CONSHOHOCKEN PA 19428
Alethia Young director C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Bell William F. Jr. director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
David P Southwell director C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421